WF 10

Drug Profile

WF 10

Alternative Names: IMMUNOKINE; OXO-K993; TCDO; Tetrachlorodecaoxide; Tetrachlorodecaoxygen; WF10

Latest Information Update: 22 Mar 2016

Price : $50

At a glance

  • Originator Nuvo Research
  • Developer Crescita Therapeutics; Fraunhofer Institute for Molecular Biology and Applied Ecology; Nuvo Research
  • Class Halogens; Oxides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetic foot ulcer; Radiation injuries
  • No development reported Cancer; Rheumatoid arthritis
  • Discontinued Allergic rhinitis; Hepatitis C; HIV infections

Most Recent Events

  • 21 Dec 2015 Discontinued - Phase-II for Allergic rhinitis (In the elderly, In adults) in Germany (IV)
  • 21 Dec 2015 Discontinued - Phase-II for Allergic rhinitis in Canada (IV)
  • 10 Nov 2015 Phase-II clinical trials in Allergic rhinitis in Canada (IV) before November 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top